Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio abierto que compara AAA817 con el estándar de atención en el tratamiento de adultos con mCRPC positivo para PSMA previamente tratados y cuya enfermedad progresó durante o después de la terapia dirigida con [177Lu]Lu-PSMA (PSMAcTION)

19 de septiembre de 2026 actualizado por: Novartis Pharmaceuticals

PSMAcTION: Un estudio de fase II/III, abierto, internacional, multicéntrico y aleatorizado de AAA817 frente al estándar de atención en el tratamiento de participantes adultos con cáncer de próstata metastásico positivo para PSMA resistente a la castración que progresó durante o después de [177Lu]Lu-PSMA Terapia dirigida

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.

Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Descripción detallada

Study CAAA817A12201 consists of 2 parts: a randomized, open-label, international, multicenter, phase II study (Phase II) to collect more information to support the proposed dose of AAA817 and a randomized, open-label, international, multicenter, 2- arm phase III study (Phase III) aimed to evaluate the efficacy and safety of proposed dose of AAA817 vs. investigator's choice of standard of care (SoC) in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had treatments with ARPI and taxane-based chemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy. The purpose of the phase II part (Phase II) of this study is to collect additional information to support proposed phase III dose of AAA817.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

443

Fase

  • Fase 2
  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Novartis Pharmaceuticals
  • Número de teléfono: +41613241111

Ubicaciones de estudio

    • New South Wales
      • Darlinghurst, New South Wales, Australia, 2010
        • Reclutamiento
        • Novartis Investigative Site
    • Queensland
      • Herston, Queensland, Australia, 4029
        • Reclutamiento
        • Novartis Investigative Site
    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Reclutamiento
        • Novartis Investigative Site
    • São Paulo
      • São Paulo, São Paulo, Brasil, 01308-050
        • Reclutamiento
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasil, 05652-000
        • Reclutamiento
        • Novartis Investigative Site
      • Seoul, Corea del Sur, 03080
        • Reclutamiento
        • Novartis Investigative Site
      • Seoul, Corea del Sur, 05505
        • Reclutamiento
        • Novartis Investigative Site
      • Seoul, Corea del Sur, 06591
        • Reclutamiento
        • Novartis Investigative Site
      • Seoul, Corea del Sur, 03722
        • Reclutamiento
        • Novartis Investigative Site
    • Arizona
      • Scottsdale, Arizona, Estados Unidos, 85258
        • Reclutamiento
        • Honor Health Research Institute
        • Investigador principal:
          • Michael Gordon
        • Contacto:
    • California
      • Los Angeles, California, Estados Unidos, 90073
        • Reclutamiento
        • VA Greater LA Healthcare System
        • Contacto:
        • Investigador principal:
          • Gholam Reza Berenji
      • Palo Alto, California, Estados Unidos, 94304-1207
        • Reclutamiento
        • VA Palo Alto Health Care System
        • Investigador principal:
          • Minal Vasanawala
        • Contacto:
      • Palo Alto, California, Estados Unidos, 94304
        • Reclutamiento
        • Stanford University Medical Center
        • Investigador principal:
          • Hong Song
        • Contacto:
      • Santa Barbara, California, Estados Unidos, 93105
        • Reclutamiento
        • Sansum Clinic
        • Investigador principal:
          • Gregg Newman
        • Contacto:
      • Santa Monica, California, Estados Unidos, 90404
        • Reclutamiento
        • Saint Johns Cancer Institute
        • Investigador principal:
          • Przemyslaw Twardowski
        • Contacto:
    • Colorado
      • Denver, Colorado, Estados Unidos, 80218
        • Reclutamiento
        • Rocky Mountain Cancer Centers
        • Investigador principal:
          • Manojkumar Bupathi
        • Contacto:
    • Connecticut
      • Hartford, Connecticut, Estados Unidos, 06102
        • Reclutamiento
        • Hartford Hospital
        • Investigador principal:
          • Andrew Salner
        • Contacto:
    • Florida
      • Miami, Florida, Estados Unidos, 33173
      • Orlando, Florida, Estados Unidos, 32804
        • Reclutamiento
        • AdventHealth
        • Investigador principal:
          • Ravi Shridhar
        • Contacto:
    • Georgia
      • Athens, Georgia, Estados Unidos, 30607
        • Reclutamiento
        • University Cancer and Blood Center LLC
        • Contacto:
        • Investigador principal:
          • Petros Nikolinakos
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Emory University
        • Investigador principal:
          • Shahid Sattar Ahmed
        • Contacto:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Reclutamiento
        • University of Chicago
        • Investigador principal:
          • Mohammad Atiq
        • Contacto:
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Reclutamiento
        • Indiana University
        • Investigador principal:
          • Nabil Adra
        • Contacto:
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Reclutamiento
        • University of Kansas Hospital
        • Investigador principal:
          • Xinglei Shen
        • Contacto:
    • Louisiana
      • Metairie, Louisiana, Estados Unidos, 70006
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Reclutamiento
        • Beth Israel Deaconess Medical Center
        • Investigador principal:
          • David J Einstein
        • Contacto:
      • Boston, Massachusetts, Estados Unidos, 02115
        • Reclutamiento
        • Dana Farber Cancer Institute
        • Investigador principal:
          • Xiao Wei
        • Contacto:
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Reclutamiento
        • WA Uni School Of Med
        • Investigador principal:
          • Jeff Michalski
        • Contacto:
          • Collin Welch
          • Número de teléfono: 314-454-8293
          • Correo electrónico: c.welch@wustl.edu
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68154
        • Reclutamiento
        • Nebraska Cancer Specialists
        • Investigador principal:
          • Samuel Mehr
        • Contacto:
    • New Jersey
      • Voorhees Township, New Jersey, Estados Unidos, 08043
        • Reclutamiento
        • New Jersey Urology LLC
        • Contacto:
        • Investigador principal:
          • Gordon Brown
    • New York
      • New York, New York, Estados Unidos, 10029
        • Reclutamiento
        • Mount Sinai Hosp Med School
        • Investigador principal:
          • Randy Yeh
        • Contacto:
      • Syracuse, New York, Estados Unidos, 13210
        • Reclutamiento
        • Associated Med Professionals of NY
        • Investigador principal:
          • Steven Finkelstein
        • Contacto:
      • The Bronx, New York, Estados Unidos, 10467
        • Reclutamiento
        • Montefiore Medical Center
        • Investigador principal:
          • Benjamin A Gartrell
        • Contacto:
    • Ohio
      • Gahanna, Ohio, Estados Unidos, 43230
        • Reclutamiento
        • Central Ohio Urology Group
        • Investigador principal:
          • Benjamin Martin
        • Contacto:
    • Oregon
      • Springfield, Oregon, Estados Unidos, 97477
        • Reclutamiento
        • Oregon Urology Institute
        • Investigador principal:
          • Bryan Mehlhaff
        • Contacto:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19111
        • Reclutamiento
        • Fox Chase Cancer Center
        • Contacto:
        • Investigador principal:
          • Matthew Zibelman
    • South Carolina
      • Myrtle Beach, South Carolina, Estados Unidos, 29572
        • Reclutamiento
        • Carolina Urologic Research Center
        • Investigador principal:
          • Neal D Shore
        • Contacto:
    • Texas
      • Dallas, Texas, Estados Unidos, 75251
        • Reclutamiento
        • Texas Oncology
        • Contacto:
        • Investigador principal:
          • Michael P Herman
      • San Antonio, Texas, Estados Unidos, 78229
    • Utah
      • Murray, Utah, Estados Unidos, 84107
        • Reclutamiento
        • Utah Intermountain Medical Center
        • Investigador principal:
          • David Gill
        • Contacto:
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Reclutamiento
        • Virginia Cancer Specialists
        • Investigador principal:
          • Gregory Scott Sibley
        • Contacto:
      • Roanoke, Virginia, Estados Unidos, 24014
        • Reclutamiento
        • Onco Hemato Asso of SW Virginia
        • Investigador principal:
          • David Buck
        • Contacto:
    • Washington
      • Seattle, Washington, Estados Unidos, 98109-1024
        • Reclutamiento
        • Fred Hutchinson Cancer Research Center
        • Contacto:
        • Investigador principal:
          • Ruben Raychaudhuri
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Reclutamiento
        • Medical College Of Wisconsin
        • Investigador principal:
          • Deepak Kilari
        • Contacto:
      • Hong Kong, Hong Kong, 999077
        • Reclutamiento
        • Novartis Investigative Site
      • Beersheba, Israel, 8457108
        • Reclutamiento
        • Novartis Investigative Site
      • Haifa, Israel, 3109601
        • Reclutamiento
        • Novartis Investigative Site
      • Jerusalem, Israel, 9112001
        • Reclutamiento
        • Novartis Investigative Site
      • Petah Tikva, Israel, 4941492
        • Reclutamiento
        • Novartis Investigative Site
      • Ramat Gan, Israel, 5265601
        • Reclutamiento
        • Novartis Investigative Site
      • Tel Aviv, Israel, 6423906
        • Reclutamiento
        • Novartis Investigative Site
      • Chiba, Japón, 2608717
        • Reclutamiento
        • Novartis Investigative Site
      • Fukuoka, Japón, 8128582
        • Reclutamiento
        • Novartis Investigative Site
      • Fukuoka, Japón, 8110213
        • Reclutamiento
        • Novartis Investigative Site
      • Fukuoka, Japón, 8120033
        • Reclutamiento
        • Novartis Investigative Site
      • Fukushima, Japón, 9601295
        • Reclutamiento
        • Novartis Investigative Site
      • Ishikawa, Japón, 9208641
        • Reclutamiento
        • Novartis Investigative Site
      • Kyoto, Japón, 6068507
        • Reclutamiento
        • Novartis Investigative Site
    • Chiba
      • Kashiwa, Chiba, Japón, 2778577
        • Reclutamiento
        • Novartis Investigative Site
    • Hokkaido
      • Sapporo, Hokkaido, Japón, 0608648
        • Reclutamiento
        • Novartis Investigative Site
    • Hyōgo
      • Kobe, Hyōgo, Japón, 6500047
        • Reclutamiento
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japón, 2360004
        • Reclutamiento
        • Novartis Investigative Site
    • Kuala Lumpur
      • Putrajaya, Kuala Lumpur, Malasia, 62250
        • Reclutamiento
        • Novartis Investigative Site
    • Selangor
      • Petaling Jaya, Selangor, Malasia, 46050
        • Reclutamiento
        • Novartis Investigative Site
      • Petaling Jaya, Selangor, Malasia, 46150
        • Reclutamiento
        • Novartis Investigative Site
      • Huxquilucan, México, 52763
        • Reclutamiento
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, México, 14050
        • Reclutamiento
        • Novartis Investigative Site
      • Beijing, Porcelana, 100036
        • Reclutamiento
        • Novartis Investigative Site
      • Beijing, Porcelana, 100034
        • Reclutamiento
        • Novartis Investigative Site
      • Guangzhou, Porcelana, 510060
        • Reclutamiento
        • Novartis Investigative Site
      • Shanghai, Porcelana, 200025
        • Reclutamiento
        • Novartis Investigative Site
      • Shanghai, Porcelana, 200032
        • Reclutamiento
        • Novartis Investigative Site
      • Tianjin, Porcelana, 300480
        • Reclutamiento
        • Novartis Investigative Site
      • Tianjin, Porcelana, 300300
        • Reclutamiento
        • Novartis Investigative Site
    • Fujian
      • Fuzhou, Fujian, Porcelana, 350025
        • Reclutamiento
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, Porcelana, 430022
        • Reclutamiento
        • Novartis Investigative Site
      • Wuhan, Hubei, Porcelana, 430030
        • Reclutamiento
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, Porcelana, 210006
        • Reclutamiento
        • Novartis Investigative Site
      • Nanjing, Jiangsu, Porcelana, 210029
        • Reclutamiento
        • Novartis Investigative Site
    • Liaoning
      • Shenyang, Liaoning, Porcelana, 110011
        • Reclutamiento
        • Novartis Investigative Site
    • Shanxi
      • Xian, Shanxi, Porcelana, 710032
        • Reclutamiento
        • Novartis Investigative Site
      • Xian, Shanxi, Porcelana, 710061
        • Reclutamiento
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, Porcelana, 610041
        • Reclutamiento
        • Novartis Investigative Site
      • Singapore, Singapur, 119228
        • Reclutamiento
        • Novartis Investigative Site
      • Singapore, Singapur, 168583
        • Reclutamiento
        • Novartis Investigative Site
      • Singapore, Singapur, 258499
        • Reclutamiento
        • Novartis Investigative Site
      • Basel, Suiza, 4031
        • Reclutamiento
        • Novartis Investigative Site
      • Bellinzona, Suiza, 6500
        • Reclutamiento
        • Novartis Investigative Site
      • Bern, Suiza, 3010
        • Reclutamiento
        • Novartis Investigative Site
      • Taipei, Taiwán, 10002
        • Reclutamiento
        • Novartis Investigative Site
      • Taipei, Taiwán, 11217
        • Reclutamiento
        • Novartis Investigative Site
      • Taipei, Taiwán, 103616
        • Reclutamiento
        • Novartis Investigative Site
      • Taoyuan, Taiwán, 33305
        • Reclutamiento
        • Novartis Investigative Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 100 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Masculino

Descripción

Inclusion Criteria: ∙

  • adults ≥ 18 years of age.
  • ECOG performance status of 0 to 2.
  • histopathological and/or cytological confirmation of adenocarcinoma of the prostate.
  • PSMA-positive disease as assessed by PSMA PET/CT scan using an approved PSMA imaging agent as protocol instructed,
  • castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
  • Prior treatments with an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy.
  • ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization
  • eGFR as requested by the sponsor

Exclusion Criteria:

  • Any investigational agents within 28 days prior to the day of randomization.
  • Any 225Ac-based investigational compound used prior to the day of randomization.
  • Participants with a history of CNS metastases who are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity.
  • Concurrent acute kidney injury (renal failure developed between 48 hours to 7 days) or chronic kidney disease (at least 3 months of ongoing renal injury)
  • Baseline xerostomia ≥ Grade 2 by CTCAE v.5
  • History of uncontrolled hypertension, myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/or clinically active significant cardiac disease
  • History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 2 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, non-invasive malignant colon polyps that have been removed).

Other protocol-defined inclusion/exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Phase II: AAA817 Dose B

AAA817 will be given for a number of cycles; a cycle = 8 weeks

The investigational treatment is AAA817

Otros nombres:
  • [225Ac]Ac-PSMA-617)

Investigational treatment is the Dose B of AAA817

Otros nombres:
  • [225Ac]Ac-PSMA-617
Comparador activo: Phase III: Investigator's choice of SoC

Participants will be given Standard of Care (SOC) treatment per Investigator's choice.

The control treatment in Phase III is investigator's choice of SoC

Experimental: Phase II: AAA817 Dose A

AAA817 Dose A will be given for a number of cycles: a cycle = 8 weeks

The investigational treatment is AAA817

Otros nombres:
  • [225Ac]Ac-PSMA-617)

Investigational treatment is the Dose B of AAA817

Otros nombres:
  • [225Ac]Ac-PSMA-617
Experimental: Phase III: Recommended Phase 3 Dose of AAA817

Rp3D of AAA817 will be given for a number of cycles; a cycle = 8 weeks

The investigational treatment is AAA817

Otros nombres:
  • [225Ac]Ac-PSMA-617)

Investigational treatment is the Dose B of AAA817

Otros nombres:
  • [225Ac]Ac-PSMA-617

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Biochemical response rate (Phase II)
Periodo de tiempo: from date of randomization up to approximately 24 months

Biochemical response rate as defined as the percentage of participants who achieved a ≥ 50% decrease from baseline that is confirmed by a second measurement

from date of randomization up to approximately 24 months
Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II
Periodo de tiempo: from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later

Safety defined as the type, incidence and severity of AEs and SAEs, and deaths

from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later
Tolerability of the proposed dose of AAA817- Phase II
Periodo de tiempo: From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817

Percentage of participants who experienced Dose interruptions, reductions, discontinuation, dose intensity and duration of exposure

From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817
Radiographic progression-free survival (rPFS)- Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis

from date of randomization up to approximately 24 months
Overall survival (OS)- Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants who are alive or who are lost to follow-up at the time of analysis

from date of randomization up to approximately 24 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Radiographic progression-free survival (rPFS)- Phase II
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis

from date of randomization up to approximately 24 months
Progression free survival (PFS)- Phase II
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of Participants meeting Progression Free Survival

from date of randomization up to approximately 24 months
Overall response rate (ORR)- Phase II
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR)

from date of randomization up to approximately 24 months
Disease control rate (DCR)- Phase II
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants with BOR of CR, PR, stable disease (SD) or non-CR/non-PD

from date of randomization up to approximately 24 months
Overall survival (OS)- Phase II
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants who are alive or who are lost to follow-up at the analysis data cut-off

from date of randomization up to approximately 24 months
Progression free survival (PFS) -Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants with PFS -defined as the time from date of randomization to first documented progression

from date of randomization up to approximately 24 months
Overall response rate (ORR)- Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

ORR is defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR)

from date of randomization up to approximately 24 months
Disease control rate (DCR) -Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

DCR is defined as the percentage of participants with BOR of confirmed CR, PR, stable disease (SD) or Non-CR/Non progressive disease (PD)

from date of randomization up to approximately 24 months
Duration of response (DoR)- Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants with confirmed DoR defined as duration of time between the date of first documented response (CR or PR) and progression or death due to any cause, whichever occurs first.

from date of randomization up to approximately 24 months
Time to first radiographic soft tissue progression (TTSTP)- Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants with confirmed first radiographic progression in soft tissue

from date of randomization up to approximately 24 months
First symptomatic skeletal event (TTSSE)_Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants with confirmed skeletal event is defined as new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, or requirement for radiation therapy to relieve bone pain, or death due to any cause, whichever occurs first

from date of randomization up to approximately 24 months
Prostate specific antigen (PSA) response -Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

PSA50 is defined as the percentage of participants who achieved a confirmed ≥ 50% decrease from baseline

from date of randomization up to approximately 24 months
Patient reported disease related symptoms and health-related quality of life (HRQoL): Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

Percentage of participants who had a Change from baseline on FACT-P Prostate Cancer Subscale (PCS)

from date of randomization up to approximately 24 months
Time to worsening on the Worst Pain: Phase III
Periodo de tiempo: from date of randomization up to approximately 24 months

Time to worsening on the Worst Pain defined as the time from randomization to the first occurrence of worsening on the Worst Pain item (brief pain inventory - short form (BPI-SF)) of at least 30% of baseline or minimum of 2 points increase from baseline, or death due to any cause, whichever occurs first. BPI-SF is a self-reported questionnaire to evaluate pain intensity (severity) and impact of pain on the participant's daily functioning (interference).

from date of randomization up to approximately 24 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de febrero de 2025

Finalización primaria (Estimado)

27 de junio de 2028

Finalización del estudio (Estimado)

19 de julio de 2033

Fechas de registro del estudio

Enviado por primera vez

17 de diciembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

16 de enero de 2025

Publicado por primera vez (Actual)

17 de enero de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

19 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir